Individuals suffering from lung adenocarcinoma carrying EGFR mutations have gained recognition as a powerful treatment modality in conjunction with a targeted EGFR-TKI, this EGFR-TKI (osimertinib).this EGFR-TKI (osimertinib), utilized in nonclinical research within animal models, has offered informative discoveries into its efficacy and safety.This investigation is aimed at optimising the this EGFR-TKI (osimertinib) dosing regimen in animal models with the aim to achieve the best clinical effects and reduce potential adverse effects.assessing the most effective dosage of this EGFR-TKI (osimertinib) in animal models is the first critical demand in this research…
